Metformin Improves Vascular Function in Insulin-Resistant Rats

Hypertension

Volumn 35, Issue 1, 2000, Pages 108-

  Katakam, Prasad V G ^a   Ujhelyi, Michael R ^a   Hoenig, Margarethe ^a   Miller, Allison W ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Blood pressure; Insulin resistance; Metformin; Nitric oxide; Relaxation

Indexed keywords

METFORMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFECT; ENDOTHELIUM CELL; HYPERTENSION; INSULIN RESISTANCE; MEAN ARTERIAL PRESSURE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT; RISK ASSESSMENT; RISK FACTOR;

ACETYLCHOLINE; ANIMALS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; ENDOTHELIUM, VASCULAR; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; MALE; METFORMIN; NITRIC OXIDE; NITROARGININE; RATS; RATS, SPRAGUE-DAWLEY; TRIGLYCERIDES; VASODILATION;

EID: 0033958239     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/01.HYP.35.1.108     Document Type: Article

References (20)

1. Yudkin JS. Hyperinsulinaemia, insulin resistance, microalbuminuria and the risk of coronary heart disease. Ann Med. 1996; 28:433-438.
2. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998; 339:229-234.
3. Turner R, for the UK Prospective Diabetes Study UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352:837-853.
4. Balkau B, Shipley M, Jarrett RJ, Pyörälä K, Pyörälä M, Forhan A, Eschwege E. High blood glucose concentration is a risk factor for mortality in middle-aged non-diabetic men. Diabetes Care. 1998; 21:360-367.
5. Dressler P, Bailey SR, Matsuda M, DeFronzo RA. Insulin resistance and coronary artery disease. Diabetologia. 1996; 39:1345-1350.
6. Després JP, Lamarche B, Mauriége P, Cantin B, Dagenais GR, Moorjani S, Lupien PJ. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996; 334:952-957.
7. Turner R, for the UK Prospective Diabetes Study UKPDS Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998; 352:854-865.
8. Miller AW, Hoenig ME, Ujhelyi MR. Mechanisms of impaired endothelial function associated with insulin resistance. J Cardiovasc Pharmacol Ther. 1998; 3:125-134.
9. Verma S, Bhanot S, Yao L, McNeill JH. Defective endothelium-dependent relaxation in fructose-hypertensive rats. Am J Hypertens. 1996; 9:370-376.
10. Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, Shulman GI. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med. 1998; 338:867-872.
11. Fanghanel G, Sanchez-Reys L, Trujillo C, Sotres D, Espinosa-Campos J. Metformin’s effects on glucose and lipid metabolism in patients with secondary failure to sulfonylureas. Diabetes Care. 1996; 19:1185-1189.
12. Sundaresan P, Lykos D, Daher A, Diamond T, Morris R, Howes LG. Comparative effects of glibenclamide and metformin on ambulatory blood pressure and cardiovascular reactivity in NIDDM. Diabetes Care. 1997; 20:692-697.
13. Bhalla RC, Toth KF, Tan E, Bhatty RA, Mathias E, Sharma RV. Vascular effects of metformin: possible mechanisms for its antihypertensive action in the spontaneously hypertensive rat. Am J Hypertens. 1996; 9:570-576.
14. Verma S, Bhanot S, McNeill JH. Antihypertensive effects of metformin in fructose-fed hyperinsulinemic, hypertensive rats. J Pharmacol Exp Ther. 1994; 271:1334-1337.
15. Nakamura Y, Ohya Y, Onaka U, Fujii K, Abe I, Fujishima M. Inhibitory action of insulin sensitizing agents on calcium channels in smooth muscle cells from resistance arteries of guinea pig. Br J Pharmacol. 1998; 123:675-682.
16. Verma S, Bhanot S, McNeill JH. Decreased vascular reactivity in metformin-treated fructose-hypertensive rats. Metabolism. 1996; 9:1053-1055.
17. ωnitroarginine, elevates serum triglyceride and cholesterol and lowers hepatic fatty acid oxidation. J Nutr. 1996; 126:2563-2567.
18. Salehi A, Parandeh F, Lundquist I. The nitric oxide synthase inhibitor NG-nitro-L-arginine methyl ester potentiates insulin secretion stimulated by glucose and L-arginine independently of its action on ATP-sensitive K+ channels. Biosci Rep. 1998; 18:19-28.
19. Marfella R, Acampora R, Verrazzo G, Ziccardi P, DeRosa N, Guinta R, Giugliano D. Metformin improves hemodynamic and rheological responses to L-arginine in NIDDM patients. Diabetes Care. 1996; 19:934-939.
20. Chenx, Panek K, Rembold CM. Metformin relaxes rat tail artery by repolarization and resultant decreases in calcium influx and intracellular calcium. J Hypertens. 1997; 15:269-274.